Work

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer.

Year: 2014

Type: article

Abstract: In the era of genomic sequencing rapid strides have been made in understanding the molecular underpinnings of non-small cell lung cancer (NSCLC) and resulted in the development of highly effective therapies targeting specific molecular subsets of the disease. Response rates (RR) have increased dramatically from ~30% with cytotoxic chemotherapy to greater than 60% with biologic therapies such as erlotinib in patients with tumors harboring specific molecular alterations. However, despite the impressive activity of targeted therapy, durable responses are uncommon and tumors tend to develop resistance to treatment within months. Thus, there is a pressing need for the development of newer modalities of treatment for advanced lung cancer.

Source: Europe PMC (PubMed Central)

DOI: 10.3978/j.issn.2218-6751.2014.09.02

Authors: Arun Rajan, James L Gulley

Institutions: National Institutes of Health, National Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institutes of Health